SRx posts FY digital net sales of USD 5.0 million, up more than 65 times

Reuters12-06 06:20
SRx posts FY digital net sales of USD 5.0 million, up more than 65 times

SRX Health Solutions Inc. reported its annual results for the fiscal year ended September 30, 2025, following a significant restructuring that shifted its focus exclusively to the pet health and wellness business. For the year, digital channel sales totaled USD 5.0 million. Adjusted EBITDA from continuing operations was negative USD 1.8 million. The company recorded one-time legal, professional, and financing fees of USD 1.7 million and other single occurrence expenses of USD 0.4 million during the period. Prior-year figures for continuing operations are not presented, as the pet health and wellness business only became the reporting entity after the reverse takeover completed in April 2025, and previous operations were discontinued following bankruptcy proceedings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SRX Health Solutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-026452), on December 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment